Recent news on Ventavis

Pulmonary Hypertension Association Names Recipients of 2007 Award ...  -  May 22, 2007
PR Newswire (press release),In January 2007, Actelion acquired CoTherix, Inc., whose product Ventavis(R) is approved and marketed in the United States for the treatment of patients

Actelion announces first quarter results 2007  -  Apr 19, 2007
PharmaLive.com (press release),We successfully concluded the integration of CoTherix within only a few weeks, adding Ventavis® to our PAH franchise in the US.

Actelion Announces First Quarter Results 2007  -  Apr 18, 2007
Primenewswire (press release),We successfully concluded the integration of CoTherix within only a few weeks, adding Ventavis(r) to our PAH franchise in the US We obtained a positive

Gilead's Atripla, Lower Costs Provide Lift To First Quarter  -  Apr 22, 2007
BioWorld Online,That deal gave Actelion a second marketed PAH product in Ventavis (iloprost), an inhaled, synthetic prostacyclin analogue that gained FDA approval in 2004.

Aradigm Revisited: CEO Adds Input to Analysis  -  Mar 29, 2007
Seeking Alpha,Just to show the relative worth of an approved drug in this space, Ventavis, an inhaled PAH drug that CoTherix shepherded through the approval process,

Aradigm Focuses on Inhaled Drugs  -  Mar 9, 2007
Seeking Alpha,Just to show the relative worth of an approved drug in this space, Ventavis, an inhaled PAH drug that CoTherix shepherded through the approval process,

Actelion Announces Full Year 2006 Financial Results  -  Feb 21, 2007
Primenewswire (press release),I expect that Tracleer(r), Ventavis(r) and Zavesca(r) will continue to grow in the coming years, as the result of the favorable characteristics each

Actelion Announces Full Year 2006 Financial Results  -  Feb 22, 2007
PharmaLive.com (press release),I expect that Tracleer®, Ventavis® and Zavesca® will continue to grow in the coming years, as the result of the favorable characteristics each medication

Specialty Infusion Brings New Challenges, Solutions to Payers  -  Feb 12, 2007
Atlantic Information Services, Inc.,Mather also suggested that plans take a second look at certain self-administered drugs, such as Ventavis (iloprost) for pulmonary arterial hypertension.

Actelion Ltd. Announces Successful Completion of its Cash Tender ...  -  Jan 9, 2007
PharmaLive.com (press release),CoTherix, Inc. licensed the exclusive US rights to Ventavis® from Schering AG, which currently markets Ventavis® in Europe and Australia.

Switzerland's Actelion seals acquisition of CoTherix  -  Jan 9, 2007
Pharma Times (subscription),...will now be getting hold of CoTherix' Ventavis (iloprost) Inhalation Solution, the only approved inhaled therapy for the treatment of PAH in the USA.

Preventing Lung Cancer  -  Jan 3, 2007
ABC30.com,Preventing Lung CancerIloprost (Ventavis) works by boosting levels of a compound called PGI2, which lung cancer patients have low levels of.

Preventing Lung Cancer  -  Jan 17, 2007
WFtv.com,ILOPROST: Patients take three pills, two times a day of a drug called Iloprost -- marketed as Ventavis. It's a synthetic compound that basically mimics the

Zacks Analyst Interview Highlights: Pfizer, CoTherix and Gilead ...  -  Dec 5, 2006
Business Wire (press release),CoTherix markets Ventavis for pulmonary arterial hypertension (PAH), as well as having a potential big drug in mid-stage trials called Fasudil.

Combo Therapy Superior for Pulmonary Arterial Hypertension  -  Dec 1, 2006
MedPage Today,1 -- Combining Ventavis (iloprost) with Tracleer (bosentan) may improve clinical and functional outcomes in pulmonary arterial hypertension, according to a

Actelion Ltd. Announces Commencement of Cash Tender Offer for ...  -  Dec 8, 2006
PharmaLive.com (press release),CoTherix, Inc. licensed the exclusive US rights to Ventavis® from Schering AG, which currently markets Ventavis® in Europe and Australia.

Biotech Has Lackluster Month of November  -  Dec 3, 2006
Drug Newswire (press release),Swiss-based Actelion Ltd plans to acquire CoTherix, Inc., which markets Ventavis (iloprost), the only approved inhaled therapy for the treatment of

CoTherix Reports Third Quarter Results  Nov 2, 2006
Net product sales for Ventavis(R) (iloprost) Inhalation Solution in the third quarter of 2006 were $18.4 million, an increase of 13 percent over the second ... -Drug Newswire (press release), CoTherix Loss Narrows  Nov 2, 2006
CoTherix (CTRX - commentary - Cramer's Take) reported a narrower third-quarter loss thanks to strong sales of its drug Ventavis for pulmonary arterial ... -TheStreet.com CoTherix Reports Third Quarter Results  Nov 1, 2006
..."In addition to the strong sales of Ventavis, we initiated clinical pharmacokinetic testing of fasudil and are on track to begin our Phase II trials in the ... -Earthtimes.org CoTherix to Webcast Presentations at Two Upcoming Investor ...  Oct 27, 2006
CoTherix currently markets Ventavis(r) (iloprost) Inhalation Solution in the United States for the treatment of PAH (WHO Group I). The Company is also ... -PR Newswire (press release), Zacks Bull and Bear of the Day Highlights: CoTherix, Sony, Grey ...  Nov 3, 2006
The company’s first product, Ventavis (iloprost) Inhalation Solution, launched in March 2005 for the treatment of pulmonary arterial hypertension (PAH). ... -Business Wire (press release), StretInsider.com Pre-Open Movers 11/02  Nov 2, 2006
Net product sales for Ventavis Inhalation Solution in the third quarter of 2006 were $18.4 million, an increase of 13 percent over the second quarter of 2006 ... -StreetInsider.com (subscription), Zacks Analyst Interview Highlights: CoTherix, Xoma, Ltd., Novartis ...  Sep 20, 2006
We talked primarily about the target market for their two drugs, Ventavis and Fasudil, which address the pulmonary arterial hypertension and stable angina ... -Business Wire

Exercise and Respiratory Training Ease Life With Pulmonary ...  Sep 19, 2006
Baseline drug therapy included Tracleer (bosentan), Revatio (sildenafil), Ventavis (iloprost), Flolan (epoprostenol), beraprost, and calcium channel blockers. ... -MedPage Today

CoTherix to Webcast Presentations at Two Upcoming Investor ...  Aug 29, 2006
CoTherix currently markets Ventavis(R) (iloprost) Inhalation Solution in the United States for the treatment of PAH (WHO Group I). The Company is also ... -PR Newswire

Actelion Announces Definitive Agreement to Acquire US-Based ...  -  Nov 19, 2006
Earthtimes.orgThis relationship was extended with CoTherix's clinical STEP trial investigating the combined use of Tracleer(R) and Ventavis(R). Based on that relationship

Actelion Announces Definitive Agreement to Acquire US-Based ...  -  Nov 19, 2006
PR Newswire (press release),Strengthening Actelion's strong role in advancing PAH therapy - Strengthening the reach of Ventavis(R) in the United States - Immediate positive effect

Actelion Announces Definitive Agreement to Acquire US-Based ...  -  Nov 20, 2006
Drug Newswire (press release),CoTherix currently markets Ventavis(R) (iloprost), the only approved inhaled therapy for the treatment of Pulmonary Arterial Hypertension in the United

Zacks Analyst Interview Highlights: Pfizer, CoTherix and Gilead ...  -  Dec 5, 2006
Business Wire (press release),CoTherix markets Ventavis for pulmonary arterial hypertension (PAH), as well as having a potential big drug in mid-stage trials called Fasudil.

Actelion buys US biotech firm for $420m  -  Nov 22, 2006
In-PharmaTechnologist.com,California-based CoTherix last year introduced Ventavis, the only US-approved inhaled prostacyclin treatment for the condition, which Actelion estimates

Actelion Adding PAH Power With $420M CoTherix Buyout  -  Nov 21, 2006
BioWorld Online,It would give Actelion a second marketed product in PAH - Ventavis (iloprost), an inhaled, synthetic prostacyclin analogue that gained FDA approval Dec.

Combo Therapy Superior for Pulmonary Arterial Hypertension  -  Dec 1, 2006
MedPage Today,1 -- Combining Ventavis (iloprost) with Tracleer (bosentan) may improve clinical and functional outcomes in pulmonary arterial hypertension, according to a

Actelion's Adept Acquisition  -  Nov 22, 2006
Motley FoolCoTherix's PAH drug, Ventavis, was approved in the US in late 2004, and sales of the drug have been ramping up at a nice rate. Its 2006 sales are expected

Actelion to Buy CoTherix for $420 Mln, Shares Up  -  Nov 21, 2006
ReutersCoTherix early last year introduced Ventavis, the only US-approved inhaled treatment for the condition, which Actelion estimates will generate 2007 sales of

Rival buys Bay Area's CoTherix  -  Nov 21, 2006
Inside Bay Area,CoTherix makes Ventavis, which like Tracleer helps treat pulmonary arterial hypertension, a potentially fatal disease where the blood pressure increases in

Actelion to buy CoTherix  -  Nov 21, 2006
San Jose Mercury News,Actelion's drug, Tracleer, was approved in 2001 and CoTherix began selling Ventavis in the United States in March last year.

Swiss biopharm to buy CoTherix for $420M  -  Nov 20, 2006
Bizjournals.com,CoTherix markets Ventavis, an inhaled therapy for treatment of pulmonary arterial hypertension. Subject to regulatory clearance and other customary closing

Actelion to Buy CoTherix for $420 Mln, Shares Soar  -  Nov 20, 2006
ReutersThe Swiss firm expects sales of Ventavis, a pulmonary arterial hypertension drug marketed by US-based CoTherix, to contribute more than $100 million to its

Actelion to acquire CoTherix  -  Nov 21, 2006
newratings.comThe Brisbane, California-based CoTherix currently markets Ventavis, which is the only approved inhaled therapy for treating Pulmonary Arterial Hypertension

Actelion CoTherix Deal Is Excellent -C Suisse  -  Nov 20, 2006
newratings.comLeveraging the US commercialization rights to Ventavis is key, an analyst says. "Arguably, Actelion with its leading position in the PAH field should be

Playing the Biotech Shuffle  -  Nov 15, 2006
Barron's (subscription)Its first drug, Ventavis was approved by the Food and Drug Administration in 2005, and could generate sales this year of almost $69 million.

Actelion Ltd. Announces Commencement of Cash Tender Offer for ...  -  Dec 8, 2006
PharmaLive.com (press release),CoTherix, Inc. licensed the exclusive US rights to Ventavis® from Schering AG, which currently markets Ventavis® in Europe and Australia.

Actelion Ltd. Announces Commencement of Cash Tender Offer for ...  -  Dec 7, 2006
PrimeZone (press release),CoTherix, Inc. licensed the exclusive US rights to Ventavis(r) from Schering AG, which currently markets Ventavis(r) in Europe and Australia.

New drug could prevent lung cancer  -  Nov 22, 2006
News 8 Austin,Patients take three pills, two times a day of a drug called Iloprost -- marketed as Ventavis. It's a synthetic compound that basically mimics the activity

CoTherix Bought By Swiss Firm  -  Nov 20, 2006
TheStreet.comIn 2007, Actelion expects sales of the inhaled PAH drug Ventavis to contribute more than $100 million to its product revenue. PAH is a chronic,

Actelion to Buy CoTherix for $420M  -  Nov 20, 2006
Houston Chronicle,Actelion said the two companies have had a long working relationship, reenforced by the co-testing of their Tracleer and Ventavis pulmonary arterial

Actelion to buy US-based CoTherix for $420 mln  -  Nov 20, 2006
ReutersThe Swiss firm expects sales of Ventavis, a pulmonary arterial hypertension drug marketed by CoTherix, to contribute more than $100 million to its product

Actelion buys US biopharma co Cotherix for 420 mln usd  -  Nov 19, 2006
Forbes,Cotherix, which is headquartered in Brisbane, California, is maker of Ventavis (iloprost), the only approved inhaled therapy for the treatment of Pulmonary

Credit Suisse Ups Actelion Target To CHF250  -  Nov 21, 2006
newratings.comExpects a boost from sales of CoTherix's key drug Ventavis. Says the deal will be earnings accretive in '08 and will boost net profit by 6% in that year.

Preventing Lung Cancer  -  Dec 6, 2006
ABC7Chicago.com,ILOPROST: Patients take three pills, two times a day of a drug called Iloprost -- marketed as Ventavis. It's a synthetic compound that basically mimics the

Biotech Has Lackluster Month of November  -  Dec 3, 2006
Drug Newswire (press release),Swiss-based Actelion Ltd plans to acquire CoTherix, Inc., which markets Ventavis (iloprost), the only approved inhaled therapy for the treatment of

CoTherix Reports Second Quarter Results  Aug 2, 2006
Net product sales for Ventavis® (iloprost) Inhalation Solution in the second quarter of 2006 were $16.2 million, up 12 percent from the previous quarter. ... -Yahoo! News

CoTherix 2Q Loss Widens  Aug 2, 2006
...year ago. Revenue rose to $16.2 million from $4.2 million last year, on sales of Ventavis which was launched in March. The drug ... -Houston Chronicle

CoTherix Posts Wider Loss In Q2; Reiterates Revenue Guidance Of ...  Aug 2, 2006
Net product sales for Ventavis Inhalation Solution in the second quarter of 2006 were $16.2 million, up 12% from the previous quarter. ... -Trading Markets

Crystal Research Associates, LLC Issues Executive Informational ...  Jul 31, 2006
CoTherix currently markets Ventavis® (iloprost) Inhalation Solution, approved by the US Food and Drug Administration (FDA) in December 2004 and launched in ... -Market Wire

CoTherix to Host Conference Call on August 2, 2006 to Announce ...  Jul 17, 2006
CoTherix currently markets Ventavis® (iloprost) Inhalation Solution in the United States for the treatment of PAH (WHO Group I). CoTherix and the CoTherix ... -Yahoo! News

CoTherix to Webcast Presentation at the CE Unterberg Emerging ...  Jul 7, 2006
CoTherix currently markets Ventavis(R) (iloprost) Inhalation Solution for the treatment of pulmonary arterial hypertension (PAH) in the United States in ... -Boursorama

CoTherix Licenses Exclusive Rights to Develop and Commercialize ...  Jun 28, 2006
CoTherix currently markets Ventavis Inhalation Solution in the United States for the treatment of pulmonary arterial hypertension (WHO Group I). CoTherix and ... -MSN Money

Cotherix Shares Edge Higher  Jun 29, 2006
2011. Monane said the company will probably see revenue of over $70 million in 2006 from its pulmonary hypertension drug Ventavis. ... -Houston Chronicle

Zacks Bull and Bear of the Day Highlights: CoTherix, Solectron ...  Jul 3, 2006
The company's first product, Ventavis (iloprost) Inhalation Solution, launched in March 2005 for the treatment of pulmonary arterial hypertension (PAH). ... -Business Wire



CoTherix Reports First Quarter Results  May 3, 2006
Net product sales from the Company's Ventavis® Inhalation Solution in the first quarter of 2006 were $14.5 million, up 32 percent from $11.0 million in the ... - Yahoo! News

CoTherix to Webcast Presentation at the Rodman & Renshaw Global ...  May 5, 2006
CoTherix markets Ventavis® (iloprost) Inhalation Solution in the United States for the treatment of pulmonary arterial hypertension (PAH) in patients with ... - Yahoo! News

CoTherix Up on Analyst Rating  May 4, 2006
The company booked revenue of $14.5 million from sales of its inhaled pulmonary arterial hypertension treatment Ventavis, up from $345,000 a year ago. ... - Houston Chronicle

United Therapeutics moves on to ovarian cancer drug, new labs  Apr 27, 2006
...strength. In only nine months of 2005, sales for CoTherix’ Ventavis generate revenues of $23.9 million for the small company. ... - Business Gazette

CoTherix to Host Conference Call on May 3, 2006, to Announce First ...  Apr 21, 2006
CoTherix's Ventavis® (iloprost) Inhalation Solution was approved by the FDA in December 2004 for the treatment of pulmonary arterial hypertension (PAH) in ... - Yahoo! News





CoTherix Appoints Abhay Joshi as EVP and Chief Technical Officer  11 Apr 2006
..."His experience will be invaluable as he contributes to our plans for pipeline expansion, both through formulation enhancements to Ventavis as well as in ... - Yahoo! News

CoTherix launches trial of Ventavis in combination with sildenafil ...  Mar 30, 2006
CoTherix, Inc., (CTRX) announced the initiation of a phase III trial of Ventavis (iloprost) Inhalation Solution in combination with sildenafil citrate. ... - Therapeutics Daily (subscription)

CoTherix Initiates Trial of Ventavis in Combination With ...  Mar 8, 2006
...(Nasdaq: CTRX) today announced the initiation of a Phase III trial of Ventavis(R) (iloprost) Inhalation Solution in combination with sildenafil citrate. ... - PR Newswire

First Patient Enrolled in CoTherix REVEAL Registry  Apr 4, 2006
CoTherix's Ventavis® (iloprost) Inhalation Solution was approved by the FDA in December 2004 for the treatment of pulmonary arterial hypertension (PAH) in ... - Yahoo! News

CoTherix, Inc. Reports Fourth Quarter and Year End 2005 Results  Mar 8, 2006
Net product sales from the company's Ventavis® Inhalation Solution in the fourth quarter of 2005 were $11.0 million, up 30 percent from $8.4 million in the ... - Yahoo! News

Myogen helped by Thelin delay?  Mar 28, 2006
In addition to Actelion, the big players in this market are Pfizer`s Revatio, United Therapeutics` Remodulin, GlaxoSmithKline`s Flolan and CoTherix`s Ventavis. ... - Monsters and Critics.com

CoTherix Initiates Combination Trial of PAH Drug  Mar 9, 2006
CoTherix has initiated a phase III trial of Ventavis inhalation solution in combination with sildenafil citrate for the treatment of pulmonary arterial ... - International News Service

CoTherix narrows 4Q loss  Mar 8, 2006
...million. Sales of the drug Ventavis totaled about $11 million for the quarter and $23.9 million since it's launch in March 2005. ... - BusinessWeek

PAH: market ripe for expansion as big pharma interest increases  Mar 27, 2006
...sparked by the launch of three new therapies and formulations in the US - United Therapeutics' IV Remodulin (treprostinil), CoTherix' Ventavis (iloprost), and ... - Pharmaceutical Business Review

Encysive Shares Tumble On FDA Thelin Approvable Letter  Mar 27, 2006
...therapies for the condition include the prostacyclins Remodulin (treprostinil sodium, from United Therapeutics Corp.) and the inhaled Ventavis (iloprost, from ... - BioWorld Online (subscription)



CoTherix to Host Conference Call on March 8, 2006 to Announce ...  Feb 23, 2006
CoTherix's Ventavis(R) (iloprost) Inhalation Solution was approved by the FDA in December 2004 for the treatment of pulmonary arterial hypertension (PAH) in ... - PR Newswire,

CoTherix: Ventavis sales ahead of Street  Jan 19, 2006
The company forecast sales of its Ventavis inhaled prostacyclin therapy of about $11 million, up 30 percent from the third quarter. ... - BusinessWeek

CoTherix sees Q4 Ventavis sales at $11 million  Jan 19, 2006
Jan 19 (Reuters) - CoTherix Inc. (CTRX.O: Quote, Profile, Research) on Thursday said it expected net product sales for Ventavis, a pulmonary arterial ... - Reuters

CoTherix Announces Fourth Quarter Ventavis Sales and 2006 Revenue ...  Jan 19, 2006
19 /PRNewswire-FirstCall/ -- CoTherix, Inc. (Nasdaq: CTRX - News) today announced that preliminary net product sales of Ventavis®(iloprost) Inhalation ... - Yahoo! News

CoTherix Announces Fourth Quarter Ventavis Sales and 2006 Revenue ...  Jan 19, 2006
19 /PRNewswire-FirstCall/ -- CoTherix, Inc. (NASDAQ:CTRX) today announced that preliminary net product sales of Ventavis(R)(iloprost) Inhalation Solution in ... - Biotech Intelligence

CoTherix Announces Fourth Quarter Ventavis Sales and 2006 Revenue ...  Jan 19, 2006
...today announced that preliminary net product sales of Ventavis(R)(iloprost) Inhalation Solution in the fourth quarter of 2005 totaled approximately $11.0 ... - PharmaLive.com

CoTherix Announces Fourth Quarter Ventavis Sales and 2006 Revenue ...  Jan 19, 2006
Ventavis Sales Increase 30 Percent Over Previous Quarter SOUTH SAN FRANCISCO, Calif., Jan. 19 /PRNewswire-FirstCall/ -- CoTherix, Inc. ... - PR Newswire

CoTherix to Webcast Presentation From Merrill Lynch Conference  Jan 30, 2006
CoTherix's Ventavis® (iloprost) Inhalation Solution was approved by the FDA in December 2004 for the treatment of pulmonary arterial hypertension (PAH) in ... - Yahoo! News

This site is for informational purposes only--it does not offer medical advice or sell health products. If you need assistance, contact your physician or healthcare professional